Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MultiCell Technologies Inc (MCET)
OTHER OTC:MCET
Holding MCET?
Track your performance easily
MCET Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
0.14% Other Institutional Investors
99.86% Public Companies and
Individual Investors
MCET FAQ
What was MultiCell Technologies Inc’s price range in the past 12 months?
Currently, no data Available
What is MultiCell Technologies Inc’s market cap?
Currently, no data Available
When is MultiCell Technologies Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MultiCell Technologies Inc’s earnings last quarter?
Currently, no data Available
Is MultiCell Technologies Inc overvalued?
According to Wall Street analysts MultiCell Technologies Inc’s price is currently Overvalued.
Does MultiCell Technologies Inc pay dividends?
MultiCell Technologies Inc does not currently pay dividends.
What is MultiCell Technologies Inc’s EPS estimate?
MultiCell Technologies Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MultiCell Technologies Inc have?
MultiCell Technologies Inc has 5,000,949,000 shares outstanding.
What happened to MultiCell Technologies Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MultiCell Technologies Inc?
Currently, no hedge funds are holding shares in MCET
---
Company Description
MultiCell Technologies Inc
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The firm develops novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer. Its therapeutic development platform includes several patented techniques used to isolate, characterize and differentiate stem cells from human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company was founded on April 28, 1970 and is headquartered in Woonsocket, RI.
---
---